TABLE OF CONTENTS I
LIST OF FIGURES VIII
LIST OF CHARTS XIII
EXECUTIVE SUMMARY 18
1.1 U.S. MARKET FOR DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY 18
1.2 TREND ANALYSIS BY SEGMENT 19
1.3 BLOOD GLUCOSE MONITORING MARKET 20
1.4 DIABETIC POPULATION 21
1.5 INSULIN 22
1.6 INSULIN SYRINGES 23
1.7 INSULIN PENS. 24
1.8 INSULIN PUMPS 24
1.9 ORAL ANTIDIABETIC DRUGS 25
1.9.1 Price Analysis 25
1.9.2 Market Analysis 26
1.10 LEADING COMPETITORS IN THE DIABETES DEVICES MARKET . 27
1.11 LEADING COMPETITORS IN THE INSULIN AND ANTIDIABETIC DRUG MARKET 28
RESEARCH METHODOLOGY 29
2.1 RESEARCH SCOPE 29
2.2 IDATA’S 9-STEP METHODOLOGY 29
Step 1: Project Initiation & Team Selection 30
Step 2: Prepare Data Systems and Perform Secondary Research 31
Step 3: Preparation for Interviews & Questionnaire Design 32
Step 4: Performing Primary Research 33
Step 5: Research Analysis: Establishing Baseline Estimates 35
Step 6: Market Forecast and Analysis 35
Step 7: Identify Strategic Opportunities 37
Step 8: Final Review and Market Release 38
Step 9: Customer Feedback and Market Monitoring 39
OVERVIEW OF DIABETES 40
3.1 INTRODUCTION 40
3.2 MAIN TYPES OF DIABETES 40
3.2.1 Type 1 Diabetes 40
3.2.2 Type 2 Diabetes 40
3.2.3 Gestational Diabetes 41
3.2.4 Prediabetes 41
3.3 DIABETES COMPLICATIONS 42
3.4 RISK FACTORS ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES 44
3.5 SIGNS AND SYMPTOMS 46
3.6 MONITORING . 47
3.6.1 Initial Diagnosis 47
3.6.2 Blood Glucose Monitoring Systems 48
3.6.3 Urinary Glucose Monitoring 49
3.6.4 Noninvasive and Minimally Invasive Monitoring Devices 49
3.7 TREATMENT 50
3.7.1 Lifestyle Measures . 50
3.7.2 Insulin . 51
3.7.3 Oral Antidiabetic Drugs 51
3.7.4 Injectable Antidiabetic Drugs 52
3.8 DRUG DELIVERY 52
3.8.1 Insulin Syringes 52
3.8.2 Insulin Pens 52
3.8.3 Insulin Pumps 52
3.8.4 Inhaled Insulin 53
3.8.5 Insulin Patches 53
3.9 EMERGING TECHNOLOGIES 54
3.10 MARKET OVERVIEW 55
3.11 MARKET ANALYSIS BY SEGMENT 57
3.12 TREND ANALYSIS AND FORECAST BY SEGMENT 61
3.13 MARKET DRIVERS AND LIMITERS 64
3.13.1 Market Drivers 64
3.13.2 Market Limiters 65
3.14 COMPETITIVE ANALYSIS 67
DIABETES IN THE U.S. 77
4.1 DIABETES PREVALENCE 77
4.2 DIABETES INCIDENCE 80
4.3 DIABETES DEMOGRAPHICS 82
4.4 OBESITY PREVALENCE 85
TRADITIONAL BLOOD GLUCOSE METERS 89
5.1 INTRODUCTION 89
5.2 MARKET ANALYSIS AND FORECAST 90
5.2.1 Total Blood Glucose Monitoring Market 90
5.2.2 Total Traditional Blood Glucose Meter Market . 93
5.2.3 Professional Traditional Blood Glucose Meter Market 96
5.2.4 Personal Traditional Blood Glucose Meter Market 99
5.3 MARKET DRIVERS AND LIMITERS 102
5.3.1 Market Drivers 102
5.3.2 Market Limiters 103
5.4 COMPETITIVE ANALYSIS 105
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
6.1 INTRODUCTION 108
6.2 MARKET ANALYSIS AND FORECAST 109
6.2.1 Total Blood Glucose Monitoring Market 109
6.2.2 Continuous Glucose Monitoring System Market 112
6.3 MARKET DRIVERS AND LIMITERS 114
6.3.1 Market Drivers 114
6.3.2 Market Limiters 115
6.4 COMPETITIVE ANALYSIS 118
BLOOD GLUCOSE TEST STRIPS 120
7.1 INTRODUCTION 120
7.2 MARKET ANALYSIS AND FORECAST 121
7.2.1 Total Blood Glucose Monitoring Market 121
7.2.2 Diabetic Population Using Blood Glucose Monitor Test Strips 124
7.2.3 Total Blood Glucose Test Strip Market 125
7.2.4 Professional Blood Glucose Test Strip Market. 127
7.2.5 Personal Blood Glucose Test Strip Market 129
7.3 MARKET DRIVERS AND LIMITERS 131
7.3.1 Market Drivers 131
7.3.2 Market Limiters 132
7.4 COMPETITIVE ANALYSIS 134
LANCETS AND LANCING DEVICES 137
8.1 INTRODUCTION 137
8.2 MARKET ANALYSIS AND FORECAST 138
8.2.1 Total Blood Glucose Monitoring Market 138
8.2.2 Total Lancet and Lancing Device Market 140
8.2.3 Professional Lancet and Lancing Device Market 143
8.2.4 Personal Lancet and Lancing Device Market 146
8.3 MARKET DRIVERS AND LIMITERS 149
8.3.1 Market Drivers 149
8.3.2 Market Limiters 150
8.4 COMPETITIVE ANALYSIS 152
INSULIN 155
9.1 INTRODUCTION 155
9.1.1 Insulin Types 155
9.2 MARKET ANALYSIS AND FORECAST 159
9.2.1 Total Insulin Market . 159
9.2.2 Rapid-Acting Insulin Analogs. 163
9.2.3 Regular and Intermediate-Acting Human Insulin 165
9.2.4 Long-Acting Insulin Analog 167
9.2.5 Insulin Mixtures 169
9.3 MARKET DRIVERS AND LIMITERS 171
9.3.1 Market Drivers 171
9.3.2 Market Limiters 172
9.4 COMPETITIVE ANALYSIS 174
INSULIN SYRINGES 177
10.1 INTRODUCTION 177
10.2 MARKET ANALYSIS AND FORECAST 178
10.2.1 Total Insulin Syringe Market 178
10.2.2 Professional Insulin Syringe Market 180
10.2.3 Personal Insulin Syringe Market 182
10.3 MARKET DRIVERS AND LIMITERS 184
10.3.1 Market Drivers 184
10.3.2 Market Limiters 185
10.4 COMPETITIVE ANALYSIS 187
INSULIN PENS 190
11.1 INTRODUCTION 190
11.2 MARKET ANALYSIS AND FORECAST 191
11.3 MARKET DRIVERS AND LIMITERS 193
11.3.1 Market Drivers 193
11.3.2 Market Limiters 194
11.4 COMPETITIVE ANALYSIS 196
INSULIN PUMPS 198
12.1 INTRODUCTION 198
12.2 MARKET ANALYSIS AND FORECAST 200
12.2.1 Total Insulin Pump and Insulin Pump Infusion Set Market 200
12.2.2 Insulin Pump Market 202
12.2.3 Insulin Pump Infusion Set Market 204
12.3 MARKET DRIVERS AND LIMITERS 206
12.3.1 Market Drivers 206
12.3.2 Market Limiters 208
12.4 COMPETITIVE ANALYSIS 210
ORAL ANTIDIABETIC DRUGS 212
13.1 INTRODUCTION 212
13.2 MARKET ANALYSIS AND FORECAST 223
13.2.1 Total Oral Antidiabetic Drug Market 223
13.2.1.1 Unit Analysis.223
13.2.1.2 Price Analysis 224
13.2.1.3 Market Analysis .226
13.2.2 Alpha-Glucosidase Inhibitors 230
13.2.3 Biguanides 233
13.2.3.1 Total Biguanide Market233
13.2.3.2 Brand Name Biguanide Market 236
13.2.3.3 Generic Biguanide Market 238
13.2.4 DPP-IV Inhibitors 240
13.2.5 Sulfonylureas 243
13.2.5.1 Total Sulfonylurea Market243
13.2.5.2 Brand Name Sulfonylurea Market 246
13.2.5.3 Generic Sulfonylurea Market 248
13.2.6 Meglitinides 250
13.2.7 Thiazolidinediones 253
13.2.8 Single Pill Combinations 256
13.3 MARKET DRIVERS AND LIMITERS 259
13.3.1 Market Drivers 259
13.3.2 Market Limiters 261
13.4 COMPETITIVE ANALYSIS 263
INJECTABLE ANTIDIABETIC DRUGS 268
14.1 INTRODUCTION 268
14.2 MARKET ANALYSIS AND FORECAST 272
14.2.1 Total Injectable Antidiabetic Drug Market 272
14.2.1.1 Unit Analysis.272
14.2.1.2 Price Analysis 273
14.2.1.3 Market Analysis .274
14.2.2 GLP-1 Receptor Agonists 278
14.2.3 Amylinomimetics 281
14.3 MARKET DRIVERS AND LIMITERS 283
14.3.1 Market Drivers 283
14.3.2 Market Limiters 284
14.4 COMPETITIVE ANALYSIS 286
ABBREVIATIONS.288
LIST OF FIGURES
EXECUTIVE SUMMARY 18
RESEARCH METHODOLOGY 29
OVERVIEW OF DIABETES 40
Figure 3-1: Major Types of Diabetes and Related Pathologies 42
Figure 3-2: Risk Factors Associated with Type 1 and Type 2 Diabetes . 46
Figure 3-3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes 47
Figure 3-4: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009 49
Figure 3-5: Total Diabetes Diagnosis, Treatment and Drug Delivery Market by
Segment, U.S., 2006 – 2016 58
Figure 3-6: Trend Analysis, Growth Rates by Market Segment, U.S. Market for
Diabetics Diagnosis, Treatment and Drug Delivery, 2006 – 2016 . 62
Figure 3-7: Drivers and Limiters in the U.S. Market for Diabetes Diagnosis,
Treatment and Drug Delivery, 2009 66
Figure 3-8: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 (Part 1) 70
Figure 3-9: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 (Part 2) 71
Figure 3-10: Leading Competitors in the Devices Segment of the Total Market
for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 73
Figure 3-11: Leading Competitors in the Insulin and Antidiabetic Drug Segment
of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery,
U.S., 2009 75
DIABETES IN THE U.S. 77
Figure 4-1: Total Prevalence of Diabetes Both Diagnosed and Undiagnosed,
Adults Aged 18 – 79, U.S., 2006 – 2016 78
Figure 4-2: Incidence of Diabetes in Adults Aged 18 – 79, U.S., 2006 – 2016 80
Figure 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,
U.S., 2006 – 2016 83
Figure 4-4: Obesity Prevalence in Adults by State, Alabama to Mississippi,
U.S., 2008 (Part 1) 86
Figure 4-5: Obesity Prevalence in Adults by State, Missouri to Wyoming, U.S.,
2008 (Part 2) 87
TRADITIONAL BLOOD GLUCOSE METERS 89
Figure 5-1: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009 89
Figure 5-2: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 91
Figure 5-3: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 – 2016 94
Figure 5-4: Professional Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 . 97
Figure 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 100
Figure 5-6: Drivers and Limiters, Traditional Blood Glucose Meter Market,
U.S., 2009 104
Figure 5-7: Leading Competitors in the Traditional Blood Glucose Meter
Market, U.S., 2009 106
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
Figure 6-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 110
Figure 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 – 2016112
Figure 6-3: Drivers and Limiters, Continuous Glucose Monitoring System
Market, U.S., 2009 117
Figure 6-4: Leading Competitors in the Continuous Glucose Monitoring System
Market, U.S., 2009 118
BLOOD GLUCOSE TEST STRIPS 120
Figure 7-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 122
Figure 7-2: Diabetic Population Using Blood Glucose Monitor Test Strips, U.S.,
2006 – 2016 124
Figure 7-3: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 125
Figure 7-4: Professional Blood Glucose Test Strip Market by Segment, U.S.,
2006 – 2016 127
Figure 7-5: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 129
Figure 7-6: Drivers and Limiters, Blood Glucose Test Strips Market, U.S., 2009133
Figure 7-7: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,
2009 135
LANCETS AND LANCING DEVICES. 137
Figure 8-1: Total Blood Glucose Monitoring Market, U.S., 2006 – 2016 138
Figure 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 – 2016 141
Figure 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 –
2016 144
Figure 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 –
2016 147
Figure 8-5: Drivers and Limiters, Lancet and Lancing Device Market, U.S.,
2009 151
Figure 8-6: Leading Competitors in the Lancet and Lancing Device Market,
U.S., 2009 153
INSULIN 155
Figure 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 156
Figure 9-2: Brand Name Insulin, U.S., 2009 158
Figure 9-3: Total Market for Insulin by Segment, U.S., 2006 – 2016 161
Figure 9-4: Rapid-Acting Insulin Analog Market, U.S., 2006 – 2016 163
Figure 9-5: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006
– 2016 165
Figure 9-6: Long-Acting Insulin Analog Market, U.S., 2006 – 2016 167
Figure 9-7: Insulin Mixture Market, U.S., 2006 – 2016 169
Figure 9-8: Drivers and Limiters for the Insulin Market, U.S., 2009 173
Figure 9-9: Leading Competitors in the Insulin Market, U.S., 2009 175
INSULIN SYRINGES 177
Figure 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016 . 178
Figure 10-2: Professional Market for Insulin Syringes, U.S., 2006 – 2016 180
Figure 10-3: Personal Market for Insulin Syringes, U.S., 2006 – 2016 . 182
Figure 10-4: Drivers and Limiters for the Insulin Syringe Market, U.S., 2009 186
Figure 10-5: Leading Competitors in the Total Insulin Syringe Market, U.S.,
2009 188
INSULIN PENS 190
Figure 11-1: Insulin Pens Market, U.S., 2006 – 2016 191
Figure 11-2: Drivers and Limiters for the Insulin Pen Market, U.S., 2009 195
Figure 11-3: Leading Competitors in the Insulin Pen Market, U.S., 2009 196
INSULIN PUMPS 198
Figure 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by
Segment, U.S., 2006 – 2016 200
Figure 12-2: Insulin Pump Market, U.S., 2006 – 2016 . 202
Figure 12-3: Insulin Pump Infusion Set Market, U.S., 2006 – 2016 204
Figure 12-4: Drivers and Limiters for the Insulin Pump Market, U.S., 2009 209
Figure 12-5: Leading Competitors in the Insulin Pump Market, U.S., 2009 210
ORAL ANTIDIABETIC DRUGS 212
Figure 13-1: Oral Antidiabetic Drug Overviews, U.S., 2009 214
Figure 13-2: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 1) 215
Figure 13-3: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 2) 216
Figure 13-4: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 3) 217
Figure 13-5: Oral Antidiabetic Drugs, U.S., 2009 (Part 1) . 218
Figure 13-6: Oral Antidiabetic Drugs, U.S., 2009 (Part 2) . 219
Figure 13-7: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 1) 220
Figure 13-8: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 2) 221
Figure 13-9: Oral Antidiabetic Drugs FDA Approval and Patent Expiry, U.S.,
2009 (Part 1) 222
Figure 13-10: Oral Antidiabetic Drug Units, U.S., 2009 223
Figure 13-11: Oral Antidiabetic Drug Price Indices, U.S., 2009 225
Figure 13-12: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 –
2016 227
Figure 13-13: Alpha-Glucosidase Inhibitor Market, U.S., 2006 – 2016 231
Figure 13-14: Total Biguanide Market by Segment, U.S., 2006 – 2016 234
Figure 13-15: Brand-Name Biguanide Market, U.S., 2006 – 2016 236
Figure 13-16: Generic Biguanide Market, U.S., 2006 – 2016 238
Figure 13-17: DPP-IV Inhibitor Market, U.S., 2006 – 2016 241
Figure 13-18: Total Sulfonylurea Market by Segment, U.S., 2006 – 2016 244
Figure 13-19: Brand-Name Sulfonylurea Market, U.S., 2006 – 2016 246
Figure 13-20: Generic Sulfonylurea Market, U.S., 2006 – 2016 248
Figure 13-21: Meglitinide Market, U.S., 2006 – 2016 . 251
Figure 13-22: Thiazolidinedione (TZD) Market, U.S., 2006 – 2016 254
Figure 13-23: Single Pill Combination Market, U.S., 2006 – 2016. 257
Figure 13-24: Drivers and Limiters for the Oral Antidiabetic Drug Market, U.S.,
2009 262
Figure 13-25: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,
2009 266
INJECTABLE ANTIDIABETIC DRUGS 268
Figure 14-1: Injectable Antidiabetic Drug Indications, U.S., 2009 . 270
Figure 14-2: Injectable Antidiabetic Drugs, U.S., 2009 270
Figure 14-3: Injectable Antidiabetic Drugs, U.S., 2009 271
Figure 14-4: Injectable Antidiabetic Drugs, FDA Approval and Patent Expiry,
U.S., 2009 271
Figure 14-5: Injectable Antidiabetic Drug Units, U.S., 2009 272
Figure 14-6: Injectable Antidiabetic Drug Price Indices, U.S., 2009 273
Figure 14-7: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006
– 2016 275
Figure 14-8: GLP-1 Receptor Agonist Market, U.S., 2006 – 2016 279
Figure 14-9: Amylinomimetic Market, U.S., 2006 – 2016 281
Figure 14-10: Drivers and Limiters for the Injectable Antidiabetic Drug Market,
U.S., 2009 285
Figure 14-11: Leading Competitors in the Injectable Antidiabetic Drug Market,
U.S., 2009 287
ABBREVIATIONS 288
LIST OF CHARTS
EXECUTIVE SUMMARY 18
Chart 1-1: Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,
2006 – 2016 18
Chart 1-2: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment and
Drug Delivery Market, U.S., 2006 – 2016 19
Chart 1-3 : Blood Glucose Test Strips as a Proportion of the Total Blood Glucose
Monitoring Market, U.S., 2009 20
Chart 1-4: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 – 79, U.S., 2006 – 2016. 21
Chart 1-5: Average Onset, Peak and Duration of Insulin Types Used in the U.S.,
2009 . 22
Chart 1-6: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016 23
Chart 1-7: Insulin Pump Market by Segment, U.S., 2006 – 2016 24
Chart 1-8: Price Index Comparison, Oral Antidiabetic Drugs, U.S., 2009 25
Chart 1-9: Market Growth Analysis, Oral Antidiabetic Drugs, U.S., 2009. 26
Chart 1-10: Leading Competitors in the Combined Market for Diabetes Devices,
U.S., 2009 27
Chart 1-11: Leading Competitors in the Combined Market for Insulin and
Antidiabetic Drugs, U.S., 2009 28
RESEARCH METHODOLOGY 29
OVERVIEW OF DIABETES 40
Chart 3-1: Total Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S.,
2006 – 2016 56
Chart 3-2: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery
Market by Segment, U.S., 2009 59
Chart 3-3: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery
Market by Segment, U.S., 2016 60
Chart 3-4: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment
and Drug Delivery Market, U.S., 2006 – 2016 63
Chart 3-5: Leading Competitors in the Total Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 – 2016 . 72
Chart 3-6: Leading Competitors in the Devices Segment of the Total Market for
Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 74
Chart 3-7: Leading Competitors in the Insulin and Antidiabetic Drug Segment of
the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,
2009 . 76
DIABETES IN THE U.S. 77
Chart 4-1: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 – 79, U.S., 2006 – 2016. 79
Chart 4-2: Incidence of Diabetes in Adults Aged 18 – 79, U.S., 2006 – 2016 81
Chart 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,
U.S., 2009 84
Chart 4-4: Obesity Prevalence in Adults by State, U.S., 2008 88
TRADITIONAL BLOOD GLUCOSE METERS 89
Chart 5-1: Traditional Blood Glucose Monitors as a Proportion of the Total
Blood Glucose Monitoring Market, U.S., 2009 92
Chart 5-2: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 – 2016 95
Chart 5-3: Professional Traditional Blood Glucose Meter Market, U.S., 2006 –
2016 . 98
Chart 5-4: Personal Traditional Blood Glucose Meter Market Segmented by
Price Range, U.S., 2009 99
Chart 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 – 2016101
Chart 5-6: Leading Competitors in the Blood Glucose Monitoring Device
Market, U.S., 2009 107
CONTINUOUS GLUCOSE MONITORING SYSTEMS 108
Chart 6-1: Continuous Glucose Monitoring Systems as a Proportion of the Total
Blood Glucose Monitoring Market, U.S., 2009 111
Chart 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 – 2016 . 113
Chart 6-3: Leading Competitors in the Continuous Glucose Monitoring System
Market, U.S., 2009 119
BLOOD GLUCOSE TEST STRIPS 120
Chart 7-1: Blood Glucose Test Strips as a Proportion of the Total Blood Glucose
Monitoring Market, U.S., 2009 . 123
Chart 7-2: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 126
Chart 7-3: Professional Blood Glucose Test Strip Market by Segment, U.S.,
2006 – 2016 128
Chart 7-4: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 –
2016 130
Chart 7-5: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,
2009 136
LANCETS AND LANCING DEVICES. 137
Chart 8-1: Lancets and Lancing Devices as a Proportion of the Total Blood
Glucose Monitoring Market, U.S., 2009 139
Chart 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 – 2016 142
Chart 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 –
2016 145
Chart 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 – 2016148
Chart 8-5: Leading Competitors in the Lancet and Lancing Device Market, U.S.,
2009 154
INSULIN 155
Chart 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 . 157
Chart 9-2: Total Market for Insulin by Segment, U.S., 2006 – 2016 162
Chart 9-3: Rapid-Acting Insulin Analog Market, U.S., 2006 – 2016 164
Chart 9-4: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006 –
2016 166
Chart 9-5: Long-Acting Insulin Analog Market, U.S., 2006 – 2016 168
Chart 9-6: Insulin Mixture Market, U.S., 2006 – 2016. 170
Chart 9-7: Leading Competitors in the Insulin Market, U.S., 2009. 176
INSULIN SYRINGES 177
Chart 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 – 2016 179
Chart 10-2: Professional Market for Insulin Syringes, U.S., 2006 – 2016 181
Chart 10-3: Personal Market for Insulin Syringes, U.S., 2006 – 2016 . 183
Chart 10-4: Leading Competitors in the Total Insulin Syringe Market, U.S.,
2009 189
INSULIN PENS 190
Chart 11-1: Insulin Pen Market, U.S., 2006 – 2016 192
Chart 11-2: Leading Competitors in the Insulin Pen Market, U.S., 2009 . 197
INSULIN PUMPS 198
Chart 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by
Segment, U.S., 2006 – 2016 201
Chart 12-2: Insulin Pump Market, U.S., 2006 – 2016 203
Chart 12-3: Insulin Pump Infusion Set Market, U.S., 2006 – 2016 . 205
Chart 12-4: Leading Competitors in the Insulin Pump Market, U.S., 2009 211
ORAL ANTIDIABETIC DRUGS 212
Chart 13-1: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 – 2016228
Chart 13-2: Total Oral Antidiabetic Drug Market by Segment, U.S., 2009 229
Chart 13-3: Alpha-Glucosidase Inhibitor Market, U.S., 2006 – 2016 232
Chart 13-4: Total Biguanide Market by Segment, U.S., 2006 – 2016 235
Chart 13-5: Brand Name Biguanide Market, U.S., 2006 – 2016 237
Chart 13-6: Generic Biguanide Market, U.S., 2006 – 2016 239
Chart 13-7: DPP-IV Inhibitor Market, U.S., 2006 – 2016 242
Chart 13-8: Total Sulfonylurea Market by Segment, U.S., 2006 – 2016 245
Chart 13-9: Brand Name Sulfonylurea Market, U.S., 2006 – 2016 . 247
Chart 13-10: Generic Sulfonylurea Market, U.S., 2006 – 2016 249
Chart 13-11: Meglitinide Market, U.S., 2006 – 2016 252
Chart 13-12: Thiazolidinedione (TZD) Market, U.S., 2006 – 2016. 255
Chart 13-13: Single Pill Combination Market, U.S., 2006 – 2016 258
Chart 13-14: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,
2009 267
INJECTABLE ANTIDIABETIC DRUGS 268
Chart 14-1: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006 –
2016 276
Chart 14-2: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2009 277
Chart 14-3: GLP-1 Receptor Agonist Market, U.S., 2006 – 2016 280
Chart 14-4: Amylinomimetic Market, U.S., 2006 – 2016 282
Chart 14-5: Leading Competitors in the Injectable Antidiabetic Drug Market,
U.S., 2009 286
ABBREVIATIONS 288